832-497-2220 [email protected]

News and Blog

»News and Blog

Top-tier Chinese Pharmaceutical company profile: Qilu Pharmaceutical

Qilu Pharmaceutical is one of the leading vertically integrated pharmaceutical companies in China, focusing on the development, manufacturing, and marketing of active pharmaceutical ingredients (APIs) and finished formulations. Qilu has 12 subsidiaries and 10 manufacturing sites worldwide. In 2910 it ranked eighth in the Chinese pharmaceutical industry by sales revenue. The company is actively looking for partnerships with global colleagues via in-/out-licensing and a co-development strategy.

Trend Interpretation | Is There Still a Clinical Future for TIGIT after Astellas quietly drops out of the race

Following PD-(L)1, high-end players have quickly joined the race to develop the new star T cell immunoreceptors with immunoglobulin and ITIM domain (TIGIT). Roche, BMS, Merck and other international pharmaceutical companies have all entered. Meanwhile, in China, BeiGene, Innovent Bio, Junshi Bio, Hengrui Medicine, and other companies are also contributing to TIGIT R&D. In 2020, both Innovent and BeiGene’s TIGIT antibodies successfully initiated clinical trials.

Top-tier Chinese Pharmaceutical company profile: Luye Pharma Group

Luye Pharma Group, a member of Luye Life Sciences Group, is an international pharmaceutical company focusing on drugs targeting the central nervous system (CNS), oncology, and other therapeutic areas. The company’s three main strategic priorities are global R&D, manufacturing, and the sale of innovative medications.

Industry Research | Reflections on CRISPR’s Potential (Part 2)

On October 26, Bayer announced a huge acquisition of Asklepios, which focuses on gene therapy, for US$4 billion. Following the trend of other international pharmaceutical companies such as Novartis, Roche, and Celgene, with this acquisition Bayer has also entered the cell and gene therapy track. Since 2018, there have been more than a dozen mergers and acquisitions of cell and gene therapy companies, and the momentum has not diminished. JW Therapeutics, which focuses on cell therapy, was also listed on the Hong Kong Stock Exchange on November 3.

Industry Research | China Analgesic Drugs Market Review and Opportunity Analysis

In China, the rapid growth of the analgesic market is second only to oncology drugs. As an example, Yangtze River’s dezocine is an analgesic acting as a κ partial agonist and μ partial agonist. It leads the analgesics market in China with RMB 6 billion in sales. This article will attempt to give some of the history behind prescribing for pain, consequences of overprescribing, as well as showing some recent industry trends in China.

Industry Research | Global Market for Schizophrenia Treatments and Development Trends

Schizophrenia, as defined by the NIH National Institute of Mental Health, is a “mental disorder characterized by disruptions in thought processes, perceptions, emotional responsiveness, and social interactions.” Symptoms of schizophrenia can be psychotic ones such as hallucinations, delusions, and thought disorder, but also may include, reduced emotional expression, reduced motivation to accomplish goals, difficulty in social relationships, motor impairment, and cognitive impairment.

According to the statistics of the World Health Organization, about 20 million people worldwide are plagued by the disease.

Industry Research | Reflections on CRISPR’s Potential (Part 1)

On October 7, 2020, the high-profile 2020 Nobel Prize in Chemistry was announced. Emmanuelle Charpentier and Jennifer A. Doudna won the award for their discovery of  CRISPR/Cas9, so called genetic scissors.

CRISPR is a gene editing tool that can be precisely targeted. Since its inception in 2012, the tool has contributed to many important discoveries in basic research, plant research, and medical research. It has been selected as one of the “Top Ten Scientific Breakthroughs in the World” by Science Magazine three times in 2012, 2013 and 2015.

Three pharmaceutical companies develop RET inhibitors as therapies for lung cancer

Lung cancer is one of the most common types of malignant tumors in the world. It has become the primary cause of death from malignant tumors in China’s urban population. According to statistics from the WHO official website, in 2018, there were nearly 2.1 million newly diagnosed lung cancer cases worldwide and 1.76 million deaths.

In recent years, the incidence of non-small cell lung cancer has been increasing, and it has become the tumor with the highest fatality rate both in China and the world.

The treatment of advanced non-small cell lung cancer is first divided into targeted therapy and non-targeted therapy according to the presence or absence of driver gene mutations. In the last article, I introduced the primary therapies used to treat NSCLC. In this article, I will focus on RET inhibitors.